Berry buys Icon’s Addplan clinical trial design tech
Berry Consultants has acquired Icon’s adaptive clinical trial design software and plans to offer it alongside its own platform.
The Texas-based statistical services provider bought Addplan – a stand-alone software system used to design, simulate, and analyze innovative adaptive clinical trials – last week.
The deal will also see Icon provide support and transitional assistance to Berry Consultants for a smooth and seamless transition for existing Addplan customers.
Scott Berry said, “We very much appreciate the confidence of Icon to carry the Addplan software forward.”
He added that the technology, combined with Berry’s own FACTS system, “provides biostatisticians two very powerful, but different tools all now under the same support, development.
“Berry Consultants will be able to advise clients the appropriate software solution for their individual need. This is another step forward for Berry Consultants driving simulations and innovation across all clinical trials.”
Tom Parke, Berry’s director of software solutions, echoed the comments.
“I’ve been an admirer of the Addplan software for some years, and really like the way its scope is very complementary to that of our trial simulation software.
“I am delighted about this opportunity and appreciate Icon partnering with us on Addplan’s future development.”
He added that, initially, the systems will remain separate. However, the firm will “then look for development opportunities of integrating some of the features of both products together into one solution.”
The Addplan technology was analyzed in a review study published last year. According to the authors – who include representatives from both Icon and Berry – the technology was originally to develop confirmatory adaptive group-sequential designs.
They add that system’s modular design allows a large number of study design simulations to be completed in a short time.
According to Icon Addplan is used by FDA, EMA and Japan’s PMDA, as well as over fifty top pharmaceutical and medical device companies and academic researchers.
Image: Stock Photo Secrets